Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Clinical Research and Equipment Industry Analysis

UpdatedJun 03, 2026
DataAggregated Company Financials
Companies2
  • 7D-0.5%
  • 3M-14.8%
  • 1Y-26.9%
  • YTDn/a

In the last week, the Clinical Research and Equipment industry is up 8.4%, with ChemoMetec up 6.3%. However, the industry is down 21% over the past year. As for the next few years, earnings are forecast to decline by 11% per annum.

Industry Valuation and Performance

Has the Danish Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 04 Jun 2026DKK 11.8bDKK 3.1bDKK 1.9b19.6x6.3x3.8x
Sat, 02 May 2026DKK 10.8bDKK 3.1bDKK 1.9b17.6x5.8x3.4x
Mon, 30 Mar 2026DKK 10.9bDKK 3.1bDKK 1.9b16x5.8x3.5x
Wed, 25 Feb 2026DKK 12.1bDKK 3.1bDKK 1.9b20.5x6.3x3.9x
Fri, 23 Jan 2026DKK 19.9bDKK 3.1bDKK 1.9b35x10.3x6.3x
Sun, 21 Dec 2025DKK 20.3bDKK 3.1bDKK 1.9b34.3x10.5x6.5x
Tue, 18 Nov 2025DKK 20.7bDKK 3.1bDKK 1.9b37.4x10.7x6.6x
Thu, 16 Oct 2025DKK 18.1bDKK 3.1bDKK 1.9b32.2x9.4x5.8x
Sat, 13 Sep 2025DKK 16.8bDKK 3.1bDKK 1.9b30.2x8.7x5.4x
Mon, 11 Aug 2025DKK 14.5bDKK 725.3mDKK 132.6m51.2x109.2x20x
Wed, 09 Jul 2025DKK 16.5bDKK 725.3mDKK 132.6m56.6x124.6x22.8x
Fri, 06 Jun 2025DKK 16.7bDKK 725.3mDKK 132.6m54.1x125.7x23x
Sun, 04 May 2025DKK 15.2bDKK 725.3mDKK 132.6m50.1x114.5x20.9x
Tue, 01 Apr 2025DKK 15.4bDKK 725.3mDKK 132.6m50.9x115.8x21.2x
Thu, 27 Feb 2025DKK 21.0bDKK 683.4mDKK 122.6m61.8x171.7x30.8x
Sat, 25 Jan 2025DKK 19.1bDKK 631.7mDKK 89.8m63.6x212.8x30.2x
Mon, 23 Dec 2024DKK 18.5bDKK 631.7mDKK 89.8m62.7x206x29.3x
Wed, 20 Nov 2024DKK 16.9bDKK 631.7mDKK 89.8m55.2x187.8x26.7x
Fri, 18 Oct 2024DKK 14.7bDKK 631.7mDKK 89.8m56.2x164x23.3x
Sun, 15 Sep 2024DKK 16.2bDKK 631.7mDKK 89.8m58x180.3x25.6x
Tue, 13 Aug 2024DKK 16.0bDKK 606.5mDKK 99.3m45.8x161.5x26.4x
Thu, 11 Jul 2024DKK 15.5bDKK 606.5mDKK 99.3m45.7x156.5x25.6x
Sat, 08 Jun 2024DKK 11.6bDKK 606.5mDKK 99.3m40.2x116.6x19.1x
Mon, 06 May 2024DKK 10.1bDKK 606.5mDKK 99.3m35.9x101.3x16.6x
Wed, 03 Apr 2024DKK 12.0bDKK 606.5mDKK 99.3m48.6x121.3x19.9x
Fri, 01 Mar 2024DKK 11.7bDKK 605.1mDKK 136.8m59.3x85.2x19.3x
Sun, 28 Jan 2024DKK 9.1bDKK 647.9mDKK 171.7m40x53.1x14.1x
Tue, 26 Dec 2023DKK 8.9bDKK 647.9mDKK 171.7m38.3x51.7x13.7x
Thu, 23 Nov 2023DKK 8.2bDKK 647.9mDKK 171.7m35.3x48x12.7x
Sat, 21 Oct 2023DKK 6.4bDKK 647.9mDKK 171.7m27.3x37.4x9.9x
Mon, 18 Sep 2023DKK 8.5bDKK 647.9mDKK 171.7m36.8x49.3x13.1x
Wed, 16 Aug 2023DKK 9.1bDKK 660.6mDKK 184.0m209x49.7x13.8x
Fri, 14 Jul 2023DKK 9.5bDKK 660.6mDKK 184.0m198.6x51.5x14.4x
Sun, 11 Jun 2023DKK 10.3bDKK 660.6mDKK 184.0m206.6x56.1x15.6x
Price to Earnings Ratio

56.1x


Total Market Cap: DKK 10.3bTotal Earnings: DKK 184.0mTotal Revenue: DKK 660.6mTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Clinical Research and Equipment Industry Price to Earnings3Y Average 87.1x202420252026
Current Industry PE
    There are only 2 companies in the Danish Life Sciences Tools and Services industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 117% per year over the last three years.
  • Revenues for these companies have grown 68% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Danish Clinical Research and Equipment compare with similar industries?

DK Market-1.88%
Healthcare-3.55%
Life Sciences-0.49%
Clinical Research and Equipment-0.49%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CHEMM ChemoMetecDKK 355.001.0%
+DKK 59.2m		-32.5%PE34.9x

Latest News

GUBRA
DKK 330.20
Gubra
7D
-6.2%
1Y
-28.4%
Narrative Update • May 26

GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside

Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.
CHEMM
DKK 355.00
ChemoMetec
7D
1.0%
1Y
-32.5%